Dompé confirms its position of excellence in the self-medication sector: according to Iqvia data for 2023-2024, three of the company's products rank among the top ten new self-medication brands by value consumption in the pharmacy channel. The ranking covers the twelve-month period ending November 2024. Topping the list is Cardioritmon Colesterolo (30-capsule package), securing first place. Xamamina Reflusso (25-sachet package of 20 ml) follows closely in third place, and Collirio Alfa idratante protettivo eye drops (10 ml) ranks ninth.

Dompé's strong market performance is further validated by another Iqvia ranking. Among the ten best-selling new self-medication packages of 2023-2024, across both new and established brands, Dompé once again claims two top positions: we find Cardioritmon Colesterolo in second place, while Xamamina Reflusso takes fourth place.

These achievements mark significant milestones for one of the largest Primary & Specialty Care portfolios in Italy, comprising 50 brands and more than 170 product offerings. With a presence in more than 100,000 pharmacies in Italy and growing international distribution across 40 countries, Dompé's global presence continues to grow. The company's Primary & Specialty Care division now includes a wide range of brands well-known all over Europe, spanning over-the-counter remedies, prescription medications and medical devices covering different therapeutic areas, from pain and inflammation to respiratory and cardiovascular areas and products in the area of nutrition.

Despite entering the self-medication market only a few years ago, Dompé can already count on 13 category-leading brands, showing consistent growth of 3-4 percentage points year-over-year. The company's commitment to process excellence drives continuous product innovation, resulting in roughly two new product launches per year, enhancing both functionality and efficacy. This sustained growth is supported by major investments in research and development, which account approximately for 17% of annual revenue and surpass the industry average of 16%.

Editor's Note: The Iqvia rankings analyzed all Consumer healthcare brands (excluding parapharmacy items and accessories such as dental hygiene products, thermometers, pregnancy tests, etc.) that introduced new packaging formats between January 2023 and November 2024. Product packages already available on the market before 2023 were excluded, even in cases of corporate ownership changes.